LIVN · NASDAQ · STOCK
LivaNova (LIVN) Stock Analysis
$81.97
52W $48.82 – $85.76
68/100
$4.46B
23.5
0.87
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is LIVN Bullish or Bearish?
Bullish.
Innellis AI committee rates LivaNova (LIVN) Buy with a composite score of 68/100
, based on 5 analysts with 100% agreement.
Last updated September 05, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +6.79 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -13.21 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 3059.07). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Risk/reward is unfavorable: 4.3% downside vs 0.6% upside.
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 05, 2026
Overall Committee Score
68/100
Agreement
100%
Analysts
5
Conviction
Unanimous
Sector Rank
Top 3%
of 192 Healthcare peers
Value Analyst
bullish
65
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 15.4% shows genuine earnings power backing the valuation
Growth Analyst
bullish
77
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 4 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3059.07)
Investment Thesis Evolution
Committee score moved marginally from 68.2 to 68.2.
Comparing 2026-09-04 to 2026-09-05 (1 day apart).
Technical Analysis
RSI (14)
56.2
Neutral
MACD Histogram
0.203
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$77.67
Resistance
$81.69
Bollinger %B
0.69
Inside Bands
Price vs Moving Averages
EMA 9
$80.54
Above
EMA 21
$80.20
Above
EMA 50
$79.26
Above
EMA 200
$70.33
Above
Fundamental Analysis
Valuation
79
Growth
92
Profitability
41
Financial Health
77
Cash Flow
70
Valuation
P/E Ratio
23.5×
P/B Ratio
3.37×
PEG Ratio
0.09
Dividend Yield
0.00%
52W High
$85.76
52W Low
$48.82
Quality & Growth
ROE
-2020.8%
ROA
-930.5%
Gross Margin
6817.6%
Operating Margin
1347.6%
Revenue Growth YoY
—
Debt / Equity
0.27
AI Fundamental Assessment
P/E ratio of 23.5 (inexpensive relative to a 15-40x range); Price-to-book of 3.4x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -20.2%; Return on assets of -9.3%; Net margin of 12.8%; Gross margin of 68.2%; Current ratio of 1.45 (tight short-term liquidity); Debt-to-equity of 0.27; Free cash flow per share is positive (2.70); Most recent quarter beat estimates by 12.3%; 5 consecutive earnings beats; EPS growth accelerating (+14.0% -> +28.6% QoQ); Average YoY EPS growth of 20.0%; Analyst estimates rising over recent quarters
Get the Full LIVN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →